Body Mass Index and response to rituximab in rheumatoid arthritis

摘要: Abstract Introduction Previous studies suggested that obesity could negatively affect the response to anti-TNFα agents, but data are lacking on how it affects rituximab (RTX). We aimed determine whether body mass index (BMI) is involved in RTX RA. Methods retrospectively analyzed for 114 RA patients receiving RTX. Change from baseline DAS28, pain a visual analog scale, erythrocyte sedimentation rate, C-reactive protein level, tender and swollen joint count was at 6 months. The primary outcome decrease DAS28 ≥ 1.2. Secondary outcomes were EULAR good remission. Results At baseline, median [interquartile range] BMI 26.8 [23.8–31.1] kg/m 2 . number of with normal weight, overweight 38, 41 35, respectively. After months, 1.2 remission 44 (38.6%), 27 (23.7%) 24 (21.1%), In univariate analysis, similar among responders non-responders ≥1.2 (26.9 [24.1–30.1] vs. [23.2–31.6], P  = 0.78), (27.7 [24.3–30.7] 26.7 [22.3–31.5],  = 0.57) [24.1–30.8] [23.2–31.5],  = 0.94). Adjusted multivariable analysis confirmed lack association between different responses measures only associated decreased ΔSJC (  = 0.0276) ΔTJC  = 0.0233). Conclusion did not These help physicians choose biologic agents obese patients.